Form 4: Mira Pharmaceuticals Director Matthew Whalen Receives Stock Options
SEC Form 4
Director Matthew Whalen of Mira Pharmaceuticals was granted 25,000 stock options with a vesting schedule over one year.
Summary
- Matthew Whalen, a director at Mira Pharmaceuticals, received 25,000 stock options.
- The options were granted on December 6, 2024, with an exercise price of $1.19, which was the closing price of the company's stock on that day.
- The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the one-year anniversary.
- The options expire on December 9, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of stock option grants to a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for compensating directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- The vesting schedule of 6 months and 1 year is fairly typical, designed to incentivize long-term performance and retention.
- The exercise price being set at the closing price on the grant date is also a common practice, ensuring the options have value only if the stock price increases.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
- The grant does not have any immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/06/2024 | Grant date of the stock options. |
| 12/09/2024 | Date of the transaction and earliest transaction date. |
| 12/10/2024 | Date of signature of the form. |
| 06/06/2025 | First vesting date of 50% of the stock options. |
| 12/06/2025 | Second vesting date of the remaining 50% of the stock options. |
| 12/09/2034 | Expiration date of the stock options. |
Keywords
stock options, insider trading, executive compensation, MIRA Pharmaceuticals, Matthew Whalen, director, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.